{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:02:47Z","timestamp":1782950567741,"version":"3.54.5"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hematologic malignancies (HMs) are well-known underlying comorbidities of pyoderma gangrenosum (PG). However, studies quantifying the likelihood of PG after HMs are yet to be performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the bidirectional association between PG and several HMs, namely acute leukemia, chronic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A population-based retrospective cohort study was conducted to study the risk of HMs in patients with PG (<jats:italic>n<\/jats:italic> =\u2009302) as compared to age-, sex-and ethnicity-matched control subjects (<jats:italic>n<\/jats:italic> =\u20091,799). A case\u2013control design was used to estimate the likelihood of PG in individuals with a preexisting history of HMs. Adjusted hazard ratios (HRs) and adjusted odds ratios (ORs) were estimated by Cox regression and logistic regression, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The prevalence of preexisting HM was higher in patients with PG than in controls (6.7% vs. 0.9%, respectively). The likelihood of having PG was significantly greater among patients with a history of HM (adjusted OR, 7.88; 95% CI, 3.85\u201316.15; <jats:italic>p<\/jats:italic> &amp;lt;\u20090.001), particularly during the first year following the diagnosis. This association was significant for acute leukemia, chronic leukemia, non-Hodgkin lymphoma, and multiple myeloma but not for Hodgkin lymphoma. The incidence rate of HM was 3.3 (95% CI, 1.2\u20137.4) and 1.6 (95% CI, 0.9\u20132.6)\/1,000 person-years among patients with PG and controls, respectively. Relative to controls, patients with PG were not more likely to develop subsequent HM (adjusted HR, 2.22; 95%CI, 0.77\u20136.45; <jats:italic>p<\/jats:italic> =\u20090.142). Compared to other patients with PG, those with HM-associated PG experienced an increased all-cause mortality rate (adjusted HR, 2.19; 95%CI, 1.09\u20134.40; <jats:italic>p<\/jats:italic> =\u20090.028).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>HM, particularly acute leukemia and multiple myeloma, are associated with an elevated likelihood of provoking PG.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1425454","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T05:04:30Z","timestamp":1721883870000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Hematological malignancy-associated pyoderma gangrenosum: evaluating the magnitude of the association"],"prefix":"10.3389","volume":"11","author":[{"given":"Khalaf","family":"Kridin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moria","family":"Ankary-Khaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouhammad","family":"Kridin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samih","family":"Badarny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-020-0213-x","article-title":"Pyoderma gangrenosum","volume":"6","author":"Maverakis","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/J.CPM.2021.06.002","article-title":"Pyoderma Gangrenosum: a literature review","volume":"38","author":"Barbe","year":"2021","journal-title":"Clin Podiatr Med Surg"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1159\/000519320","article-title":"Pyoderma Gangrenosum and interleukin inhibitors: a semi-systematic review","volume":"238","author":"Ben Abdallah","year":"2022","journal-title":"Dermatology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/J.1365-2133.2011.10565.X","article-title":"Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients","volume":"165","author":"Binus","year":"2011","journal-title":"Br J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/J.REVMED.2022.06.007","article-title":"Neutrophilic dermatoses","volume":"43","author":"Delaleu","year":"2022","journal-title":"Rev Med Interne"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40257-018-0356-7","article-title":"Underlying systemic diseases in pyoderma Gangrenosum: a systematic review and meta-analysis","volume":"19","author":"Kridin","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/annonc\/mdl443","article-title":"Epidemiology of hematological malignancies","volume":"18","author":"Rodriguez-Abreu","year":"2007","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"172641","DOI":"10.1016\/J.EJPHAR.2019.172641","article-title":"Hematological malignancies and molecular targeting therapy","volume":"862","author":"Shimada","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/J.JAAD.2019.09.032","article-title":"Pyoderma gangrenosum in hematologic malignancies: a systematic review","volume":"82","author":"Montagnon","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/oxfordjournals.aje.a113439","article-title":"On the need for the rare disease assumption in case-control studies","volume":"116","author":"Greenland","year":"1982","journal-title":"Am J Epidemiol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1001\/jamadermatol.2017.6334","article-title":"Coexistent solid malignancies in pemphigus","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/J.1440-0960.1995.TB00919.X","article-title":"Pyoderma gangrenosum, erythema elevatum diutinum and IgA monoclonal gammopathy","volume":"36","author":"Wayte","year":"1995","journal-title":"Australas J Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/10428190500254299","article-title":"Bullous pyoderma gangrenosum as the presenting sign of fatal acute myelogenous leukemia","volume":"47","author":"Fox","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40257-020-00553-9","article-title":"Immune-mediated dermatoses in patients with Haematological malignancies: a comprehensive review","volume":"21","author":"Maglie","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/S40257-018-00418-2","article-title":"Neutrophilic dermatoses associated with myeloid malignancies","volume":"20","author":"Lepelletier","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/J.1365-2133.2007.08211.X","article-title":"T-cell receptor repertoire in pyoderma gangrenosum: evidence for clonal expansions and trafficking","volume":"157","author":"Brooklyn","year":"2007","journal-title":"Br J Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1159\/000512931","article-title":"Estimating the odds of ulcerative colitis-associated pyoderma Gangrenosum: a population-based case-control study","volume":"237","author":"Kridin","year":"2021","journal-title":"Dermatology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/S40257-022-00699-8","article-title":"Pyoderma Gangrenosum: An updated literature review on established and emerging pharmacological treatments","volume":"23","author":"Maronese","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1182\/BLOOD-2023-187856","article-title":"Projected global trends in hematological malignancies: incidence, mortality, and disability-adjusted life years from 2020 to 2030","volume":"142","author":"An","year":"2023","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1038\/jid.2012.130","article-title":"Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study","volume":"132","author":"Langan","year":"2012","journal-title":"J Invest Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1742-7622-2-11","article-title":"The Bradford Hill considerations on causality: a counterfactual perspective","volume":"2","author":"H\u00f6fler","year":"2005","journal-title":"Emerg Themes Epidemiol"},{"key":"ref23","first-page":"204","article-title":"The quality indigators program in Clalit Health Services: the first decade","volume":"149","author":"Cohen","year":"2010","journal-title":"Harefuah"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1425454\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T05:04:34Z","timestamp":1721883874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1425454\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":23,"alternative-id":["10.3389\/fmed.2024.1425454"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1425454","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]},"article-number":"1425454"}}